Company news
IDEAYA Biosciences, Inc. news in 2022
IDEAYA Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
December 18, 2022
IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161
December 11, 2022
IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
December 4, 2022
IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022
November 28, 2022
IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
November 27, 2022
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences
October 31, 2022
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors
October 17, 2022
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 18, 2022
IDEAYA Announces Pricing of Public Offering of Common Stock
September 13, 2022
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
September 10, 2022
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
September 5, 2022
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
August 29, 2022
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
August 28, 2022
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 14, 2022
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
July 26, 2022
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
July 26, 2022
IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
June 27, 2022
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
June 7, 2022
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 9, 2022
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
May 2, 2022
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
May 1, 2022
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors
April 5, 2022
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
March 14, 2022
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update
March 14, 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
March 13, 2022
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
March 7, 2022
IDEAYA Biosciences to Participate in Investor Conferences in March 2022
February 28, 2022
IDEAYA Biosciences to Participate in Investor Conferences in February 2022
January 31, 2022
IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
January 30, 2022
IDEAYA Biosciences Announces Corporate and Portfolio Update for J.P. Morgan 40th Annual Healthcare Conference
January 9, 2022
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
January 4, 2022
IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory Board
January 3, 2022
IDEAYA Biosciences to Participate in Investor Conferences in January 2022
January 2, 2022
Decks in 2022
- Investor Presentation (November 2022)
Investor deck · 31 slides · Nov 8, 2022